All Stories

  1. Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
  2. Lung transplantation for COPD/pulmonary emphysema
  3. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era
  4. The antiviral drug presatovir for respiratory syncytial virus infection after lung transplant
  5. Gamma-glutamyltransferase is a strong predictor of secondary sclerosing cholangitis after lung transplantation for COVID-19 ARDS
  6. Eine Querschnittsuntersuchung zur Qualität der Sauerstofftherapie in drei deutschen Krankenhäusern
  7. Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study
  8. Comparative analysis of fibroblastic foci in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis
  9. Value of functional lung MRI in long term patient care after lung transplantation.
  10. Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study
  11. Sauerstoff in der Akuttherapie
  12. Eine Querschnittsuntersuchung zur Qualität der Sauerstofftherapie in drei deutschen Krankenhäusern
  13. Correspondence
  14. Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions
  15. Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation
  16. Lung transplant and severe coronary artery disease: results from a single-centre experience
  17. Better survival in SARS-2 infected patients after lung transplantation with an antibody cocktail
  18. Lung transplantation in HIV-positive patients: a European retrospective cohort study
  19. Chest Infections After Lung Transplantation
  20. Graphic narrative based informed consent for bronchoscopy improves satisfaction in patients after lung-transplantation: A randomized controlled trial
  21. Five-year Outcome of an Early Everolimus-based Quadruple Immunosuppression in Lung Transplant Recipients: Follow-up of the 4EVERLUNG Study
  22. Kidney injury after lung transplantation: Long-term mortality predicted by post-operative day-7 serum creatinine and few clinical factors
  23. Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis
  24. Nutzen und Risiken der Behandlung mit Sauerstoff
  25. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients
  26. Stille Hypoxie bei COVID-19: Eine Fallserie
  27. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction—A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial
  28. German S3 Guideline: Oxygen Therapy in the Acute Care of Adult Patients
  29. Silent Hypoxia in COVID-19: A Case Series
  30. Lung Transplantation for Acute Respiratory Distress Syndrome
  31. Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies
  32. Quality of domiciliary oxygen therapy in adults with chronic respiratory diseases
  33. Sauerstoff in der Akuttherapie beim Erwachsenen
  34. COVID-19 in lung transplant recipients—Risk prediction and outcomes
  35. Clinical decision making is improved by BioFire Pneumonia Plus in suspected lower respiratory tract infection after lung transplantation: Results of the prospective DBATE‐IT * study
  36. Sauerstofftherapie in der Akut- und Notfallmedizin
  37. Clinical decision making is improved by rapid multiplex-PCR in suspected lower respiratory tract infection after lung transplantation in a prospective cohort study
  38. S3-Leitlinie Sauerstoff in der Akuttherapie beim Erwachsenen
  39. The Transplant Evaluation Rating Scale Predicts Clinical Outcomes 1 Year After Lung Transplantation: A Prospective Longitudinal Study
  40. Video Consultation During the COVID-19 Pandemic: A Single Center's Experience with Lung Transplant Recipients
  41. Oxygen Treatment in COVID-19
  42. Pulmonary Fibroelastotic Remodelling Revisited
  43. Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy
  44. Delayed non-myeloablative irradiation to induce long-term allograft acceptance in a large animal lung transplantation model
  45. Characteristics and clinical implications of pleural effusions after lung transplantation: A retrospective analysis of 195 thoracocenteses in 113 patients
  46. Sauerstofftherapie bei Kandidaten zur Lungentransplantation − eine monozentrische retrospektive Analyse von 807 Patienten
  47. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity
  48. Impact of unilateral diaphragm elevation on postoperative outcomes in bilateral lung transplantation – a retrospective single‐center study
  49. Lung transplantation for sarcoidosis: outcome and prognostic factors
  50. Viral load-guided immunosuppression after lung transplantation (VIGILung)—study protocol for a randomized controlled trial
  51. A Before-and-After Study of Evidence-Based Recommendations for On-Call Bronchoscopy
  52. Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie
  53. Viral load Guided Immunosuppression after Lung Transplantation (VIGILung) – study protocol for a randomized controlled trial
  54. Impact of COVID-19 on Lung Transplant Activity in Germany—A Cross-Sectional Survey
  55. Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation
  56. Exceptional LAS Requests in Eurotransplant: Analysis of an 8-year Effort to Improve Lung Allocation for Precarious Patients
  57. Impact of donor lung quality on post‐transplant recipient outcome in the Lung Allocation Score era in Eurotransplant – a historical prospective study
  58. Adherence is associated with a favorable outcome after lung transplantation
  59. Saving those who can't wait
  60. Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infectio...
  61. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation
  62. Community-acquired respiratory viruses
  63. MRI‐derived regional flow‐volume loop parameters detect early‐stage chronic lung allograft dysfunction
  64. Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome―A consensus report from the Pulmonary Council of the ISHLT
  65. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT
  66. Lungentransplantation
  67. Oxygen Therapy for Isolated Exercise-Induced Hypoxemia Should Be Prescribed With Caution
  68. Need for and Outcomes of Intraoperative Extracorporeal Circulatory Support in Lung Transplantation for Pulmonary Fibrosis
  69. Predicted Total Lung Capacity Ratio between Donors and Recipients Does Not Predict Outcomes in Non-Volume Reduced Lung Transplantation
  70. Initial immunosuppression and managing rejection
  71. Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation
  72. Transplantation of donor lungs with pulmonary embolism - a retrospective study
  73. Risk factors and outcomes of vocal cord paralysis after lung transplantation - a retrospective cohort study
  74. Lungentransplantation bei Lungenkarzinom
  75. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years
  76. O 2 saturation target of 96–100% should be abandoned
  77. Wartelistenführung und Organvermittlung zur Lungentransplantation 2018 – Aktuelles für den Pneumologen
  78. Lobe-wise assessment of lung volume and density distribution in lung transplant patients and value for early detection of bronchiolitis obliterans syndrome
  79. Detection of chronic lung allograft dysfunction using ventilation-weighted Fourier decomposition MRI
  80. Management of Spontaneous Pneumothorax and Post-Interventional Pneumothorax: German S3 Guideline
  81. Management of Spontaneous Pneumothorax and Postinterventional Pneumothorax: German S3-Guideline
  82. Heart re-transplantation in Eurotransplant
  83. Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study
  84. The burden of sinus disease in cystic fibrosis lung transplant recipients
  85. Breath volatile organic compounds of lung transplant recipients with and without chronic lung allograft dysfunction
  86. The liver-first approach for combined lung and liver transplantation
  87. The Transplant Evaluation Rating Scale (TERS): A Tool for the Psychosocial Evaluation of Lung Transplant Candidates
  88. Endobronchial Ultrasound in Suspected Non-Malignant Mediastinal Lymphadenopathy
  89. Lung allocation score: the Eurotransplant model versus the revised US model - a cross-sectional study
  90. Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis
  91. 3-and 5-Year Results of Lung Preservation with the Organ Care System: Insights from a Single-Center Experience
  92. A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients
  93. Benefits of Early Everolimus-Based Quadruple Immunosuppression Early After Lung Transplantation - Results of 4EVERLUNG, a Prospective Randomized Multicenter Trial
  94. Lung Transplantation for Scleroderma Lung Disease: Indications, Survival and Prognosis
  95. Vocal Cord Paralysis After Lung Transplantation Does Not Influence Early Outcome
  96. Community-Acquired Respiratory Viruses
  97. Technique and Outcomes of Less Invasive Lung Retransplantation
  98. Self-reported non-adherence to immunosuppressive medication in adult lung transplant recipients-A single-center cross-sectional study
  99. Infection transmission among lung transplant couples
  100. Single lung transplantation from a donor 8 months after double lung transplantation
  101. Lung transplantation after allogeneic stem cell transplantation: a pan-European experience
  102. Recent advances in extracorporeal life support as a bridge to lung transplantation
  103. DNA-based testing in lung transplant recipients with suspected non-viral lower respiratory tract infection: A prospective observational study
  104. Transplanting HCV-Infected Kidneys into Uninfected Recipients
  105. Breath VOC patterns of lung transplant recipients with and without chronic lung allograft dysfunction (CLAD)
  106. CT at onset of chronic lung allograft dysfunction in lung transplant patients predicts development of the restrictive phenotype and survival
  107. Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation
  108. In Reply
  109. Lung allocation
  110. Splenocyte Infusion and Whole-Body Irradiation for Induction of Peripheral Tolerance in Porcine Lung Transplantation: Modifications of the Preconditioning Regime for Improved Clinical Feasibility
  111. Cellular analysis in bronchoalveolar lavage: inherent limitations of current standard procedure
  112. Biodegradable stent for vanishing bronchus syndrome after lung transplantation
  113. Response
  114. “White-Out” After Lung Transplantation: A Multicenter Cohort Description of Late Acute Graft Failure
  115. Early Natural Killer Frequencies and Chronic Lung Allograft Dysfunction Two Years After Lung Transplantation
  116. Risk Factors for Intraoperative Extracorporeal Circulatory Support in Patients Undergoing Lung Transplantation for Pulmonary Fibrosis
  117. Technique and Outcomes of Less Invasive Lung Retransplantation
  118. Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score
  119. Irradiation before and donor splenocyte infusion immediately after transplantation induce tolerance to lung, but not heart allografts in miniature swine
  120. Mid-term results of bilateral lung transplant with postoperatively extended intraoperative extracorporeal membrane oxygenation for severe pulmonary hypertension†
  121. Repeated human leukocyte antigen mismatches in lung re-transplantation
  122. Response
  123. Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation
  124. An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe
  125. Phenotyping Chronic Lung Allograft Dysfunction Using Body Plethysmography and Computed Tomography
  126. Lung transplantation in the spotlight: Reasons for high-cost procedures
  127. Dichotomy in pulmonary graft- versus -host disease evident among allogeneic stem-cell transplant recipients undergoing lung transplantation: TABLE 1
  128. The burden of sinus disease in CF candidates for lung transplantation
  129. CF sinus disease after lung transplantation
  130. Exhaled nitric oxide: A biomarker for chronic lung allograft dysfunction?
  131. Risk of post-transplantation diabetes mellitus (PTDM) with different calcineurin inhibitors
  132. ICU Care Before and After Lung Transplantation
  133. Nintedanib in restrictive chronic lung allograft dysfunction after lung transplantation
  134. Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial
  135. Lung transplantation for non-cystic fibrosis bronchiectasis
  136. ‘Unacceptable’ Human Leukocyte Antigens in Lung Re-Transplantation
  137. Correlation New UNOS LAS and ET LAS
  138. Early Donor Specific Antibodies Correlate with a Distinct Peripheral Cellular Immune Phenotype after Lung Transplantation
  139. Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database
  140. Heart-Lung Transplantation for Congenital Heart Disease: A 25 Years Single Center Experience
  141. IgM Enriched Human Immunoglobulins and Rituximab Nullify the Mortality Risk Associated with Early Donor Specific Antibodies After Lung Transplantation
  142. Lung First vs. Liver First Sequence for Combined Lung and Liver Transplantation
  143. Outcomes in Lung Transplantation Following Allogeneic Stem-Cell Transplantation: A Pan-European Experience
  144. Risk Factors and Impact of Bronchial Stenoses after Lung Transplantation: Ten Year Single Center Experience with over 1,100 Patients
  145. Topical Nasal Anesthesia in Flexible Bronchoscopy – A Cross-Over Comparison between Two Devices
  146. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
  147. Prolonged Mechanical Ventilation After Lung Transplantation-A Single-Center Study
  148. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients
  149. BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma
  150. Five-year experience with intraoperative extracorporeal membrane oxygenation in lung transplantation: Indications and midterm results
  151. Allokationssysteme in der Transplantationsmedizin
  152. Chronische Abstoßung
  153. IgM-Enriched Human Intravenous Immunoglobulin-Based Treatment of Patients With Early Donor Specific Anti-HLA Antibodies After Lung Transplantation
  154. Molecular Profiling in Lung Biopsies of Human Pulmonary Allografts to Predict Chronic Lung Allograft Dysfunction
  155. Epithelial and Erythrocyte Microvesicles From Bronchoalveolar Lavage Fluid Are Elevated and Associated With Outcome in Chronic Lung Allograft Dysfunction
  156. Percutaneous dilatational tracheostomy (PDT) in trauma patients: a safe procedure
  157. Survival and spirometry outcomes after lung transplantation from donors aged 70 years and older
  158. Local Anesthetics delivered through Pleural Drainages improve Pain and Lung Function after Cardiac Surgery
  159. The impact of long-term air pollution and traffic on outcome after lung transplantation in Europe
  160. Return to work after lung-transplantation – A cross-sectional single-center study
  161. Lung transplantation for Non- Cystic fibrosis bronchiectasis: A single centre retrospective analysis of 34 patients
  162. Lung transplantation following endoscopic lung volume reduction
  163. Lung Preservation With Perfadex or Celsior in Clinical Transplantation
  164. Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study
  165. Chronic Lung Allograft Dysfunction: Oxygen-enhanced T1-Mapping MR Imaging of the Lung
  166. Gastrointestinal Endoscopy Is Safe in Patients Before and After Lung or Heart Transplantation
  167. The unusual journey of a tooth. Found but not lost?
  168. When a respiratory pathogen turns to the skin: cutaneous tuberculosis in a lung transplant patient
  169. Retrogradein situversus antegrade pulmonary preservation in clinical lung transplantation: a single-centre experience
  170. An Innovative Everolimus-Based Quadruple Low Immunosuppressive Regimen Compared to Standard Triple Regimen in Lung Transplant Recipients and Its Impact on Renal Function, Safety and Efficacy: The 4EVERLUNG Study Design
  171. Early Donor Specific Antibodies After Lung Transplantation Lead to an Increase of CD56+CD16+ NK Cells in Peripheral Blood
  172. Extracorporeal Membrane Oxygenation for Concomitant Coronary Artery Bypass Grafting and Lung Transplantation
  173. Human Intravenous Immunoglobulins With Rituximab vs. Therapeutic Plasma Exchange With Rituximab for Pre-Emptive Treatment of Early Donors Specific Antibodies After Lung Transplantation: Preliminary Result
  174. Intra-Operative Indication Extracorporeal Membrane Oxygenation for Cardiopulmonary Support During Lung Transplantation: Risk Factors and Mid-Term Results
  175. Intraoperative Cardiopulmonary Support With Extracorporeal Membrane Oxygenation in Lung Transplantation: Favorable Outcomes in High Risk Patients
  176. Perioperative ECMO Use in Lung Transplantation for Severe Pulmonary Hypertension
  177. Survival and Spirometry Outcomes Following Lung Transplantation From Donors >70 Years - Extended Criteria Coming of Age
  178. The Era Effect on Pediatric Lung Transplantation Outcomes
  179. Employment after Lung Transplantation
  180. Postoperative Weight Gain during the First Year after Kidney, Liver, Heart, and Lung Transplant: A Prospective Study
  181. Lung Transplantation for Severe Pulmonary Hypertension—Awake Extracorporeal Membrane Oxygenation for Postoperative Left Ventricular Remodelling
  182. Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation
  183. Lung Transplantation after Endoscopic Lung Volume Reduction
  184. Cardiac Mass and Function Decrease in Bronchiolitis Obliterans Syndrome after Lung Transplantation: Relationship to Physical Activity?
  185. Early donor-specific antibodies in lung transplantation: Risk factors and impact on survival
  186. Lungentransplantation
  187. Lung transplantation for interstitial lung diseases
  188. Paclitaxel-Coated Balloons in Refractory Nonanastomostic Airway Stenosis Following Lung Transplantation
  189. C1-Esterase-Inhibitor for Primary Graft Dysfunction in Lung Transplantation
  190. Introduction of the Lung Allocation Score in Germany
  191. Lung transplantation for cystic fibrosis
  192. Safety and efficacy of outpatient bronchoscopy in lung transplant recipients - a single centre analysis of 3,197 procedures
  193. Significance of new lung infiltrates in outpatients after lung and heart-lung transplantation
  194. Bronchial Wall Measurements in Patients after Lung Transplantation: Evaluation of the Diagnostic Value for the Diagnosis of Bronchiolitis Obliterans Syndrome
  195. Developing a Score of Early Postoperative Regulatory T Cell Frequency To Predict Bronchiolitis Obliterans Syndrome-Free Survival at Two Years After Lung Transplantation
  196. Donor Oxygenation Has No Impact on Postoperative Outcome After Lung Transplantation
  197. Is Routine Screening for Community-Acquired Respiratory Virus Infections in Lung Transplant Recipients Worthwhile?
  198. Postoperative Donor Specific Anti-HLA Antibodies in Lung Transplantation: Risk Factors and Impact on Mid-Term Patient and Graft Outcomes
  199. Pre-Emptive Treatment of Donor Specific Anti-HLA Antibodies in Lung Transplantation With Plasmapheresis
  200. The ‘Blood Transfusion Effect’ in Lung Transplantation - Striking Evidence for an Old Hypothesis in an Unlikely Setting
  201. The Impact of Air Pollution on Outcome After Lung Transplantation in Europe
  202. Telemedizinische Erfassung der Lungenfunktion bei Patienten nach Lungentransplantation
  203. Conventional vs. Tablet Computer-Based Patient Education following Lung Transplantation – A Randomized Controlled Trial
  204. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients
  205. Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients
  206. A relevant experimental model for human bronchiolitis obliterans syndrome
  207. Extended criteria donor lungs and clinical outcome: Results of an alternative allocation algorithm
  208. Tissue concentration of paraquat on day 32 after intoxication and failed bridge to transplantation by extracorporeal membrane oxygenation therapy
  209. Health-Related Quality of Life After Solid Organ Transplantation
  210. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients: Table 1–
  211. Lungentransplantation
  212. Lung Transplantation for Interstitial Lung Diseases and Pulmonary Hypertension
  213. Low Exercise Tolerance Correlates With Reduced Inspiratory Capacity and Respiratory Muscle Function in Recipients With Advanced Chronic Lung Allograft Dysfunction
  214. Bronchiolitis Obliterans Syndrome-Free Survival after Two Years in Patients with Higher Frequencies of Regulatory T Cells Early after Lung Transplantation
  215. C1-Esterase-Inhibitor Counteracts Severe Primary Graft Dysfunction in Lung Transplantation
  216. 1240 CHRONIC HEPATITIS E IN LUNG TRANSPLANT RECIPIENTS
  217. Comparison of an Innovative Everolimus-Containing Quadruple Immunosuppressive Regimen Versus a Standard Triple Regimen in Lung Transplant Recipients and Its Impact on Renal Function, Safety and Efficacy: The 4EVERLUNG Study Design
  218. Impact of Lung Allocation Score on Transplantation Activity and Outcomes – Initial German Experience
  219. Increasing Creatine Phosphokinase and Myglobine Levels Predict the Development of Acute Renal Failure Immediately after Combined Heart-Lung Transplantation
  220. Lung Transplantation for Pulmonary Lymphangioleiomyomatosis: Single-Centre Experience
  221. Phenotyping Established Chronic Lung Allograft Dysfunction Predicts Extracorporeal Photopheresis Response in Lung Transplant Patients
  222. Biodegradable stents after lung transplantation
  223. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience
  224. Indikationen und Ergebnisse der Lungentransplantation bei idiopathischer Lungenfibrose
  225. S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose
  226. The influence of clinical course after lung transplantation on rehabilitation success
  227. Lung transplantation on cardiopulmonary support: Venoarterial extracorporeal membrane oxygenation outperformed cardiopulmonary bypass
  228. <I>Mycobacterium intracellulare</I> bacteraemia in a double lung transplant patient [Correspondence]
  229. Renal function and survival in 200 patients undergoing ECMO therapy
  230. 12 Years of Experience in Combined Lung and Liver Transplantation - Changes Over Time and Long Term Outcome
  231. Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients
  232. Preoperative Irradiation and Donor Splenocyte Infusion Induce Tolerance in Lung, but not Heart Allografts in a Minipig Model - Role of Passenger Leukocytes
  233. Regulatory T Cells Correlate with Percent Predicted FEV1 after Lung Transplantation
  234. The Problem after Lung Transplantation for Idiopathic Pulmonary Artery Hypertension Is not the Right Ventricle - Awake ECMO for LV Remodelling
  235. The Problem after Lung Transplantation for Idiopathic Pulmonary Artery Hypertension Is not the Right Ventricle - Awake ECMO for LV Remodelling
  236. Treatment of Hepatitis E in Solid Organ Transplant Recipients
  237. Warm Perfusion of the Donor Lung for Preservation Might Have Positive Immunomodulatory Effects after Transplantation
  238. HDR brachytherapy: an option for preventing nonmalignant obstruction in patients after lung transplantation
  239. Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients
  240. The lung transplant patient in the ICU
  241. Lung transplantation for pulmonary hypertension
  242. Renal Comorbidity After Solid Organ and Stem Cell Transplantation
  243. Viremia after Lung Transplant: A Cohort Study on Risk Factors and Symptoms Associated with Detection of Epstein-Barr Virus
  244. Multicentre European study for the treatment of advanced emphysema with bronchial valves
  245. Lungentransplantation
  246. Outcome of critically ill lung transplant candidates on invasive respiratory support
  247. 143 A Web-Based Pilot Study of Judgment of the Transplant Benefit by Transplant Experts in Comparison to the Lung Allocation Score: The Eurotransplant Experience
  248. Extracorporeal Membrane Oxygenation in Awake Patients as Bridge to Lung Transplantation
  249. 327 Good Lungs for Bad Recipients and Bad Lungs for Good Recipients – Follow Up on Eurotransplant Rescue Offers
  250. 277 Lung Transplant Surgery on Cardiocirculatory Support: Extracorporeal Membrane Oxygenation Outcompetes Cardiopulmonary Bypass
  251. 218 Not the Right, but the Left Ventricle Causes the Problem after Lung Transplantation for Pulmonary Artery Hypertension – Awake ECMO for Postoperative LV Remodelling
  252. 622 Preoperative Irradiation and Donor Splenocyte Infusion Induce Tolerance in Lung, but Not Heart Allografts in a Minipig Model – Role of Passenger Leukocytes
  253. 63 Regulatory T Cells Correlate with Percent Predicted FEV1 after Lung Transplantation
  254. Spirometric Obstructive Lung Function Pattern Early After Lung Transplantation
  255. Improved Packing and Routing of Vehicles with Compartments
  256. Lung function early after lung transplantation is correlated with the frequency of regulatory T cells
  257. Rare indications for lung transplantation
  258. Graft-Protective Effects of the HMG-CoA Reductase Inhibitor Pravastatin After Lung Transplantation— A Propensity Score Analysis With 23 Years of Follow-Up
  259. Proteomic Bronchiolitis Obliterans Syndrome Risk Monitoring in Lung Transplant Recipients
  260. Transplantationsassoziierte Pathologie der Lunge
  261. Plexiform Lesions in Pulmonary Arterial Hypertension
  262. Single-Centre Experience with Oral Ribavirin in Lung Transplant Recipients with Paramyxovirus Infections
  263. 169 Clinical Significance of Cytomegalovirus (CMV) Detected by RT-PCR in Bronchoalveolar-Lavage Fluid of Stable Lung Transplant Recipients
  264. 555 FoxP3 Positive Treg Correlate with Percent Predicted FEV1 Early after Lung Transplantation
  265. 444 Pulmonary Retransplantation: A Single Center Experience
  266. Therapeutic Drug Monitoring of Mycophenolic Acid After Lung Transplantation—Is It Clinically Relevant?
  267. Incidence and outcome of abdominal surgical interventions following lung transplantation—a single center experience
  268. RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus
  269. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series
  270. Obliterative Airway Remodeling
  271. Pulmonary retransplantation in paediatric patients: a justified therapeutic option? A single-centre experience
  272. Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant
  273. Endoscopic Indicators for Obstructive Airway Complications After Lung Transplantation
  274. Incidence and impact of herpes simplex and cytomegalovirus detection in the respiratory tract after lung transplantation
  275. Self-Expanding Metallic Stent Placement with Laryngeal Mask in Lung Transplant Recipients
  276. Use of telehealth technology for home spirometry after lung transplantation: a randomized controlled trial
  277. Catheter Fragmentation and Local Lysis in Two Lung Transplant Patients with Pulmonary Embolism
  278. Lungentransplantation bei Lungenemphysem – Wer? Wann? Wie?
  279. Biopsy‐Diagnosed Renal Disease in Patients After Transplantation of Other Organs and Tissues
  280. Chronische respiratorische Insuffizienz: Rolle der Lungentransplantation
  281. Extracorporeal Membrane Oxygenation in Nonintubated Patients as Bridge to Lung Transplantation
  282. Health-Related Quality of Life in Long-Term Survivors After Heart and Lung Transplantation: A Prospective Cohort Study
  283. Obliterative airway remodelling in transplanted and non-transplanted lungs
  284. Initial Safety Evaluation Of A European Multicenter, Single Blinded And Randomized Study For The Treatment Of Advanced Emphysema With Bronchial Valves
  285. Non- Lobar Atelectasis Approach For The Treatment Of Advanced Emphysema With Bronchial Valves In A European Multicenter, Single Blinded And Randomized Study
  286. Vehicle routing with compartments: applications, modelling and heuristics
  287. Endoskopische Palliation bei Ösophagus- und Bronchialkarzinomen
  288. 423: Avoiding Mechanical Ventilation during Extracorporeal Membrane Oxygenation before Lung Transplantation Decreases Postoperative Mortality
  289. 36: Efficacy of Oral Ribavirin in Lung Transplant Recipients with Paramyxoviral Infection
  290. 160: Evaluation of the Lung Allocation Score in High Urgent and Urgent Lung Transplant Candidates in Eurotransplant
  291. 27: Lung Transplantation as Treatment for Pulmonary Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre Experience
  292. 31: Outcome of Lung Transplant Candidates on Mechanical Ventilation or Extracorporal Support
  293. 362: PTLD after Lung Transplantation – Influence of CMV Prophylaxis on Incidence – Multicentre Centre Analysis and Review of the Literature
  294. 41: Results of a Randomized Phase 2 Trial of ALN-RSV01, an RNAi Therapeutic, Lung Transplant (LTX) Patients Infected with Respiratory Syncytial Virus (RSV)
  295. 348: Splenocyte Infusion and Low Dose Irradiation Induce Peripheral Tolerance in Porcine Lung Transplantation – Modifications of the Protocol for Improved Clinical Feasibility
  296. Vibration response imaging (VRI) in lung transplant recipients
  297. Significance of patient self-monitoring for long-term outcomes after lung transplantation
  298. Indicators for steroid response in biopsy proven acute graft rejection after lung transplantation
  299. Lungentransplantation bei Mukoviszidose – ein Positionspapier
  300. Effect of Adherence to Home Spirometry on Bronchiolitis Obliterans and Graft Survival After Lung Transplantation
  301. Community-Acquired Respiratory Viral Infections in Lung Transplant Recipients: A Single Season Cohort Study
  302. Correlation of Donor Leukocyte Chimerism With Pulmonary Allograft Survival After Immunosuppressive Drug Withdrawal in a Porcine Model
  303. Are metallic stents really safe? A long-term analysis in lung transplant recipients
  304. Detection of Epstein–Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation
  305. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis
  306. Lungentransplantation
  307. Bridge to Thoracic Organ Transplantation in Patients with Pulmonary Arterial Hypertension Using a Pumpless Lung Assist Device
  308. Lung and Heart–Lung Transplantation in Children and Adolescents: A Long-term Single-center Experience
  309. Symptom experience after solid organ transplantation
  310. Intentional ABO‐Incompatible Lung Transplantation
  311. Review: Update on lung transplantation
  312. Komplikationen nach Lungentransplantation
  313. Komplikationen nach Lungentransplantation
  314. Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases
  315. 87: Advanced Chronic Kidney Disease Early after Lung Transplantation Predicts Worse Outcome
  316. 449: Celsior for Graft Preservation in Clinical Lung Transplantation
  317. 56: Clinical Indicators for Steroid Response in Biopsy Proven Acute Allograft Rejection in Lung Transplant Recipients
  318. 38: Comparison of Voriconazole Versus a Combination of Voriconazole and Caspofungin as Primary Therapy for Suspected Invasive Aspergillosis in Lung Transplant Recipients
  319. 384: ECLA vs. ECMO — Impact of Different Extracorporeal Life Support Systems as a Bridge to Lung Transplantation – A Single Center Retrospective Analysis
  320. 26: Effect of Non-Adherence to Home Spirometry on Graft Survival and Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation
  321. 36: Epstein-Barr Virus Reactivation Is Associated with Mild Clinical Symptoms during the Posttransplant Period of Lung Transplant Recipients
  322. 401: Everolimus Versus Mycophenolatemofetil in De Novo Immunosuppression after Lung Transplantation – Interims Analysis of a Prospective, Randomized, Clinical Trial
  323. 411: Home Based Exercise Training in Lung and Heart Transplant Recipients – Effects on Maximum and Endurance Exercise Capacity
  324. 65: Influence of Ischemic Time on Survival and Chronic Rejection in Lung Transplantation
  325. 487: Longitudinal Assessment of Non-Adherence with Lung Function Monitoring after Lung Transplantation
  326. 66: Lung Transplantation in Patients on Invasive Ventilation and Extracorporeal Membrane Oxygenation
  327. 380: Use of Cardiopulmonary Bypass in Patients Undergoing Minimally Invasive Bilateral Lung Transplantation
  328. Long-Term Azithromycin for Bronchiolitis Obliterans Syndrome After Lung Transplantation
  329. Interventional Lung Assist: A New Concept of Protective Ventilation in Bridge to Lung Transplantation
  330. Symptom experience after lung transplantation: impact on quality of life and adherence
  331. Lungentransplantation
  332. Bridge to Lung Transplantation With the Extracorporeal Membrane Ventilator Novalung in the Veno-Venous Mode: The Initial Hannover Experience
  333. Post-operative Nosocomial Infections After Lung and Heart Transplantation
  334. 470: Daclizumab induction therapy in clinical lung transplantation – a prospective, double-blinded, randomized trial
  335. 134: Impact of airway colonization with gram-negative bacteria on developement of bronchiolitis-obliterans-syndrome in lung transplant recipients with cystic fibrosis
  336. 450: Invasive aspergillosis in lung transplant recipients: The impact of pretransplant colonization
  337. 313: Minimally invasive lung transplantation in more than 145 patients with emphysema: It should be the standard approach
  338. 182: Time course of physical reconditioning during 3 years after lung transplantation – effects of exercise rehabilitation
  339. Clinical relevance of and risk factors for HSV-related tracheobronchitis or pneumonia: results of an outbreak investigation
  340. Long-term outcome after pulmonary retransplantation
  341. Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung
  342. 216
  343. 178
  344. 375
  345. 392
  346. Applications of Racing Algorithms: An Industrial Perspective
  347. Empirical Analysis of Locality, Heritability and Heuristic Bias in Evolutionary Algorithms: A Case Study for the Multidimensional Knapsack Problem
  348. Health-Related Quality of Life in Two Hundred-Eighty Lung Transplant Recipients
  349. Tissue Remodeling in a Bioartifical Fibromuscular Patch Following Transplantation in a Human
  350. Surveillance invasiver Fadenpilzmykosen in lungentransplantierten Patienten: Effekt antimykotischer Prophylaxe mit Itraconazol und Voriconazol. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis wi...
  351. Lungentransplantation
  352. Daily routine patient-controlled lung function testing using electronic spirometry is essential for long-term outcome following lung transplantation
  353. Health-related quality of life in 280 transplant recipients
  354. Pulmonary retransplantation for patients with the bronchiolitis-obliterans-syndrome - a single center experience
  355. Reduced size lung transplantation for fibrosis and cystic fibrosis-one year follow up
  356. Risk factors for perioperative mortality and nosocomial infections in lung transplantation
  357. Successful bridge to clinical lung transplantation using the pumpless extracorporeal lung assist device NovaLung® in patients with severe ventilation-refractory hypercapnia
  358. Lungentransplantation
  359. Evolutionary Algorithms for the Satisfiability Problem
  360. In vitro excision of adeno-associated virus DNA from recombinant plasmids: isolation of an enzyme fraction from HeLa cells that cleaves DNA at poly(G) sequences.